A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
Not Applicable
Completed
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- Registration Number
- NCT00002309
- Lead Sponsor
- Pfizer
- Brief Summary
To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count \< 100 cells/mm3.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie azithromycin's prophylactic efficacy against MAC in HIV patients with CD4 < 100 cells/mm3?
How does weekly azithromycin compare to standard-of-care MAC prophylaxis in HIV-infected immunocompromised individuals?
Which biomarkers correlate with azithromycin response in MAC prevention for CD4 < 100 HIV patients?
What are the long-term adverse event profiles of azithromycin prophylaxis in HIV-MAC patients with CD4 < 100 cells/mm3?
Are there combination therapies with azithromycin that improve MAC prevention in HIV-infected patients with low CD4 counts?
Trial Locations
- Locations (3)
San Diego Naval Hosp
🇺🇸San Diego, California, United States
Womack Army Med Ctr / Med Clinic
🇺🇸Fort Bragg, North Carolina, United States
United States Air Force Med Ctr
🇺🇸Lackland Air Force Base, Texas, United States
San Diego Naval Hosp🇺🇸San Diego, California, United States